Scotia Capital’s Fulgent Genetics FLGT Stock Holding History

Scotia Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,356	Closed	-$212K	–	891
2021 Q3	$212K	Sell	2,356 -52	-2%	-$4.73K	﹤0.01%	787
2021 Q2	$222K	Buy	+2,408	New	+$192K	﹤0.01%	768

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Scotia Capital's FLGT Position: Q4 2021 in Review

Scotia Capital sold out of Fulgent Genetics (FLGT) in Q4 2021, closing a stake of 2,356 shares — an estimated $212K sold.

Scotia Capital first reported a position in FLGT in Q2 2021 and held it in 2 quarters. The position peaked at $222K in Q2 2021. 299 funds tracked by Wall St. Rank hold FLGT as of Q4 2021.

Scotia Capital reported no remaining Fulgent Genetics position as of Q4 2021 after selling out during the quarter.
Scotia Capital sold 2,356 Fulgent Genetics shares in Q4 2021, an estimated $212K.
Scotia Capital first reported a position in Fulgent Genetics in Q2 2021 and held it in 2 quarters.
Scotia Capital's Fulgent Genetics position peaked at $222K in Q2 2021.
299 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2021.

Based on Scotia Capital's 13F filing for Q4 2021, filed 11 Feb 2022.